CARMIEL, Israel, Nov. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that Dr. David Aviezer, Ph.D., its President and Chief Executive Officer, will present at the CIBC World Markets 18th Annual Healthcare Conference. Dr. Aviezer's presentation will take place at 3:00 p.m. EST on Monday, November 5th at the Waldorf-Astoria Hotel in New York City.
Dr. Aviezer's presentation may be heard live via a simulcast link at http://www.veracast.com/webcasts/cibcwm/healthcare07/84112115.cfm. Following the live presentation, the archived webcast will be available for a period of 90 days after the presentation.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company. Its goal is to become a fully
integrated biopharmaceutical company focused on the development and
commercialization of proprietary recombinant therapeutic proteins to be
expressed through its proprietary plant cell based expression system.
Protalix's ProCellEx(TM) presents a proprietary method for the expression
of recombinant proteins that Protalix believes is safe and scalable and
will allow for the cost-effective, industrial-scale production of
recombinant therapeutic proteins. Protalix has initiated enrollment and
treatment of patients in its pivotal phase III clinical trial in the United
States of its lead product candidate, prGCD, for its enzyme replacement
therapy for Gaucher disease, a lysosomal storage disorder in humans, and
has reached an agreement with the United States Food and Drug
Administration on the final design of the pivotal phase III clinical trial
through the FDA's Special Proto
|SOURCE Protalix BioTherapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved